Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

Inclusion Criteria: * Patients 18 years of age or older * Chronic corneal epithelial disease with fluorescein staining score ≥ 6 by NEI grading scale * Reduced corneal sensation (≤ 4 cm measured by Cochet Bonnet esthesiometry) in at least one corneal quadrant * A stable ocular surface with no objective clinical evidence of significant (\> 50%) improvement/worsening of the epithelial disease in the last 30 days * Epithelial disease refractory to conventional non-surgical treatments (e.g., preservative-free artificial tears, gels or ointments; discontinuation of preserved topical drops; anti-inflammatory therapy) Exclusion Criteria: * Any active or suspected ocular infection (bacterial, viral, fungal or protozoal). * Evidence of corneal ulceration with stromal loss \> 10% * Presence of an epithelial defect ≥1.0 mm in the largest diameter in the affected eye * Presence of any size epithelial defect that has been persistent for more than 30 days * Patients unable to discontinue or intermittently remove therapeutic contact lens in the study eye (to apply drops) during the 4-week study period * History of any ocular surgery (including laser or refractive surgical procedures) in the affected eye within the 3 months prior to study enrollment * History of chemical injury within the last 6 months prior to study enrollment Known hypersensitivity to one of the components of the study or procedural medications (e.g.,fluorescein) * History of drug, medication or alcohol abuse or addiction * Use of any investigational agent within 4 weeks of screening visit * History of previous enrollment in the MSC Secretome Study at a lower dose * Participation in another clinical study at the same time as the present study * Participants who are pregnant at the time of study enrollment